|Videos|January 17, 2018

Current Guidance for C. diff Disinfection in Health Care Facilities

Barley Chironda, RPN, CIC, discusses current guidance for disinfection practices against C. diff.

Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, discusses current guidance for disinfection practices against C. diff.

Interview Transcript (modified slightly for readability):

“As for the current guidance that is important right now as far as disinfection and Clostridium difficile (C. diff), I’ll lump them into the 2 different ones that are available around the world, because I tend to do a lot of work around the world.

The most important ones in the United States alone are the Healthcare Infection Control Practices Advisory Committee (HICPAC) document, which was made I think 10 or 12 years ago; there are also documents through the Infectious Disease Society of America (IDSA).

What these 2 documents really speak to is that you need to have a disinfectant that has been checked and assessed to be sporicidal. And so, when you have a patient who has C. diff, all of those rooms need to be cleaned thoroughly with a sporicidal disinfectant. That’s one key unifying theme in most of those documents.

In addition to that, they recommend that you have to wash your hands thoroughly with soap and water because if you use an alcohol-based sanitizer, sometimes, it doesn’t get to all the nooks and crannies. But that physical, mechanical action of washing your hands is really what you need to do.

And so, narrowing it down really to the guidance documents, you want to be doing those 2 key things. First, thorough disinfection with a sporicidal agent and then you also want to do handwashing with the necessary soap and water.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.